Carregant...
Clinical Use of Dornase Alfa Is Associated with a Slower Rate of FEV(1) Decline in Cystic Fibrosis
OBJECTIVES: Randomized controlled trials of dornase alfa have shown forced expiratory volume in 1 second (FEV(1)) to improve in patients with cystic fibrosis (CF) but have not assessed change in the rate of lung function decline. We assessed the relationship of dornase alfa use and FEV(1) decline us...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4109161/ https://ncbi.nlm.nih.gov/pubmed/21438174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ppul.21388 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|